Metavia Inc (MTVA) Stock Price, Quote & News

Company Profile

MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 702 9600

Website: www.metaviatx.com

Address:

545 Concord Avenue, Suite 210, Cambridge, United States

WallStreetVice May. 13 at 10:30 PM

$HUMA $MXCT $MTVA $HLP 76

0 · Reply

durocali May. 13 at 6:58 PM

$MTVA kudos to the BTFDers who bought under $1 this week...

0 · Reply

Arttab May. 13 at 6:02 PM

$MTVA Did we miss something ?

0 · Reply

Kertzi May. 13 at 3:39 AM

$MTVA Six months ago: Reverse split. Now: back under $1. Do you understand what you're holding, dealing with here? Dong-A ST doesn't care. They never did. They have your cash, their IP is safe in Seoul, and their lawyer-CEO is collecting $750,000/year to keep the Nasdaq shell breathing. The business model isn't drug development. It's: PR → dilution → reverse split → repeat. Next R/S coming late summer. Endless offerings ahead. $148M in accumulated losses and increasing Rinse & repeat — until there's nothing left to rinse.

0 · Reply

Joefreeagent May. 13 at 1:32 AM

$MTVA congratulations to MTVA. It is very impressive to have lost 100.00% and still be listed.

0 · Reply

BULLISH1975 May. 12 at 6:14 PM

$ICU the more research I fo anout iCU- The more bullish I get!!!!! so many medications fix one issue and cause more!!!! How often do we get a device which prevents organ damage- treats SEPSIS AnD prevents Dialysis????? 6 breakthrough device destinations Phase III trial the SCD already saving lives!!!! TAM billions float 4 million dyor $MTVA $GME $GRI $TLRY

0 · Reply

BULLISH1975 May. 12 at 3:23 PM

$ICU Q1 quarterly tomorrow- FDA SAVE news due AND ICU already showing as a BUY/STRONG BUY on several technical charts!!!!! Saving lives good momentum SCD becoming SOC TAM over 20 billion per chargpt 6 breakthrough device destinations one pediatric FDA HDE device and same device in adult phase III trial. $MTVA $ENSC $GME $GRI float is 4 million shares revenue growing- add to list

0 · Reply

Gnouss May. 10 at 2:24 PM

$MTVA in 1.05 for short flip

1 · Reply

Joefreeagent May. 8 at 1:24 PM

$MTVA

2 · Reply

Kertzi May. 8 at 4:22 AM

$MTVA CEO just did a podcast talking about finding a "big pharma partner." https://www.buzzsprout.com/236855/episodes/19128116 Let me explain why that's either delusional or dishonest. MetaVia doesn't own the IPs. = Dong-A ST does. If Pfizer calls, they call Seoul — not Cambridge. MetaVia gets bypassed. This isn't a biotech. It's a Nasdaq-listed fundraising vehicle for a Korean pharma's R&D budget. Retail carries all the risk. Seoul takes all the upside.

1 · Reply

MetaVia to Present Data Highlighting DA-1726, a GLP-1/Glucagon Dual Agonist, in a Late-Breaking Poster Presentation at the EASL Congress 2026

2026-04-10T12:36:24.000Z - 4 weeks ago

MetaVia says first patient dosed in Part 3 of Phase 1 trial of DA-1726

Apr 10, 2026, 8:30 AM EDT - 4 weeks ago

MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity

2026-03-26T12:43:01.000Z - 6 weeks ago

MetaVia: Cash position adequate to fund operations into 4Q26

2026-03-26T12:41:30.000Z - 6 weeks ago

MetaVia CEO says ‘significant progress advancing our cardiometabolic portfolio’

Mar 26, 2026, 8:31 AM EDT - 6 weeks ago

MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update

2026-03-18T12:05:12.000Z - 2 months ago

MetaVia announces IRB at Clinical Pharmacology of Miami approved Phase 1 study

Mar 18, 2026, 8:00 AM EDT - 2 months ago

MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control

Mar 12, 2026, 10:30 AM EDT - 2 months ago

MetaVia Transcript: Life Sciences Virtual Investor Forum

2026-03-12T13:09:03.000Z - 2 months ago

MetaVia expands global patent protection for vanoglipel into 2035

Mar 12, 2026, 9:01 AM EDT - 2 months ago

MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035

Mar 4, 2026, 8:31 AM EST - 2 months ago

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum

Feb 25, 2026, 10:15 AM EST - 2 months ago

MetaVia Transcript: Emerging Growth Virtual Conference

Feb 17, 2026, 9:01 AM EST - 3 months ago

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference

Feb 13, 2026, 8:31 AM EST - 3 months ago

MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041

Feb 4, 2026, 8:00 AM EST - 3 months ago

MetaVia Announces Positive AI-Modeling Results from its Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets for Vanoglipel

Jan 16, 2026, 4:01 PM EST - 4 months ago

MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option

Jan 15, 2026, 9:32 AM EST - 4 months ago

MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering

Jan 5, 2026, 8:30 AM EST - 4 months ago

MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile

Dec 29, 2025, 8:31 AM EST - 4 months ago

MetaVia to Participate in and Sponsor the 10th Annual MASH-TAG 2026 Conference

Dec 22, 2025, 8:31 AM EST - 5 months ago

MetaVia Regains Compliance with Nasdaq Minimum Bid Price Requirement

Dec 2, 2025, 8:45 AM EST - 5 months ago

MetaVia Inc. Announces 1-for-11 Reverse Stock Split

Nov 7, 2025, 8:31 AM EST - 6 months ago

MetaVia Presents Positive New Phase 2a Data on Vanoglipel (DA-1241) in Patients with Presumed MASH at the AASLD The Liver Meeting® 2025

Nov 6, 2025, 8:31 AM EST - 6 months ago

MetaVia Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 4, 2025, 4:01 PM EST - 6 months ago

MetaVia to Present New Phase 1 and Pre-Clinical Data on DA-1726 at ObesityWeek® 2025

Oct 27, 2025, 8:31 AM EDT - 7 months ago

MetaVia Announces Poster Presentation on Vanoglipel (DA-1241) at the AASLD Liver Meeting

Oct 20, 2025, 8:31 AM EDT - 7 months ago

MetaVia Announces Poster Presentations on DA-1726 at ObesityWeek® 2025

Oct 14, 2025, 8:31 AM EDT - 7 months ago

MetaVia to Present at the H.C. Wainwright Liver Disease Virtual Conference

Sep 5, 2025, 7:00 AM EDT - 8 months ago

MetaVia Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aug 26, 2025, 8:31 AM EDT - 9 months ago

MetaVia to Present at Upcoming Investor and Industry Conferences

Aug 7, 2025, 8:31 AM EDT - 9 months ago

MetaVia Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 6, 2025, 8:31 AM EDT - 10 months ago

MetaVia Extends 48 mg MAD Portion of Its Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity to 8 Weeks and Announces Fifth Weekly Dose in First Patient

Aug 4, 2025, 8:31 AM EDT - 10 months ago

MetaVia Announces AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241

Jul 9, 2025, 8:31 AM EDT - 11 months ago

MetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum Tolerated Dose

Jun 21, 2025, 9:00 AM EDT - 11 months ago

MetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA's 85th Scientific Session

Jun 12, 2025, 1:00 PM EDT - 11 months ago

MetaVia Transcript: Life Sciences Investor Forum

Jun 10, 2025, 8:31 AM EDT - 1 year ago

MetaVia to Present at the Life Sciences Virtual Investor Forum June 12th

Jun 4, 2025, 8:31 AM EDT - 1 year ago

MetaVia Announces Poster Presentation on DA-1241 at the ADA's 85th Scientific Sessions

May 21, 2025, 4:25 PM EDT - 1 year ago

MetaVia Transcript: Emerging Growth Conference 82

May 14, 2025, 4:05 PM EDT - 1 year ago

MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 9, 2025, 8:01 AM EDT - 1 year ago

MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

May 7, 2025, 2:00 AM EDT - 1 year ago

MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025

Apr 23, 2025, 8:31 AM EDT - 1 year ago

MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025

Apr 22, 2025, 8:31 AM EDT - 1 year ago

MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential

Apr 15, 2025, 7:01 AM EDT - 1 year ago

MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability

Mar 20, 2025, 7:31 AM EDT - 1 year ago

MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update

Jan 10, 2025, 8:05 AM EST - 1 year ago

MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference

Nov 18, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases

Nov 13, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals to Participate in Investor Conferences in November

Nov 7, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 4, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Oct 1, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals to Participate in Investor Conferences in October

Sep 30, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Sep 3, 2024, 8:01 AM EDT - 1 year ago

NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Aug 14, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 13, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Aug 6, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity

Jul 30, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01

Jul 11, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals to Present at the Emerging Growth Conference in July

Jun 26, 2024, 9:06 AM EDT - 2 years ago

NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

WallStreetVice May. 13 at 10:30 PM

$HUMA $MXCT $MTVA $HLP 76

0 · Reply

durocali May. 13 at 6:58 PM

$MTVA kudos to the BTFDers who bought under $1 this week...

0 · Reply

Arttab May. 13 at 6:02 PM

$MTVA Did we miss something ?

0 · Reply

Kertzi May. 13 at 3:39 AM

0 · Reply

Joefreeagent May. 13 at 1:32 AM

$MTVA congratulations to MTVA. It is very impressive to have lost 100.00% and still be listed.

0 · Reply

BULLISH1975 May. 12 at 6:14 PM

0 · Reply

BULLISH1975 May. 12 at 3:23 PM

0 · Reply

Gnouss May. 10 at 2:24 PM

$MTVA in 1.05 for short flip

1 · Reply

Joefreeagent May. 8 at 1:24 PM

$MTVA

2 · Reply

Kertzi May. 8 at 4:22 AM

1 · Reply

SuperGreenToday May. 7 at 7:58 PM

$MTVA

0 · Reply

BioRich May. 7 at 6:51 PM

$SABS Hope y'all took advantage of that dip. Multi-day runner potential here. Sure, Huntavirus is going to get this some attention, but it's pipeline is impressive, and their Type 1 Diabetes treatment has some of the best results I've seen to date. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers! $MTVA $GUTS $EBS $NVAX

2 · Reply

BULLISH1975 May. 6 at 7:39 PM

$ICU up about 11% today! several catalysts due! TAM billions Device already pediatric FDA HDE approved- adult phase III readout in 12ish months- same device - market 50 times bigger! float 4 million 6 breakthrough device destinations $GME $ENSC $MTVA $GRI $GRIO dyor

0 · Reply

BULLISH1975 May. 6 at 2:42 PM

$ICU last post for today!!!! This is a $30 stock sitting at $4.50. do your research people! lots of catalysts incoming, TAM billions- device saves lives!!! one fda HDE approved product one adult phase III no debt revenue growing $MTVA $ENSC $GRI $GME

0 · Reply

BULLISH1975 May. 1 at 1:46 PM

$ICU **********If you new here! spend and hour researching and I am 99% certain you BUY!!!!!! Way under radar!!!! you will than me in a few weeks and months!!!!! lots if catalysts coming 4 million float approved device one phase III with TAM of 4 plus billion 6 breakthrough device destinations MC less than 18 million dyor $MTVA $GRI $CAR

1 · Reply

Kertzi Apr. 30 at 6:54 AM

$MTVA - 10K summary as follows : • 8 full-time employees. Eight. • Going concern warning — their own auditor doesn't believe they survive 12 months • Accumulated deficit $148.8M — market cap $7.7M • Cash runs out Q4 2026 • All IP owned by Dong-A ST (Korea). • If successful, MetaVia owes Korea $316M (!!!) in milestones. • If bankrupt, IPs returns to Korea for free. • Sole manufacturer: Dong-A ST. • Effective sole owner: Dong-A ST. This is NOT a drug company. It's a Korean parent's US mailbox, that raises retail capital to fund clinical trials. All potential upside flows to Seoul, all risk sits with Nasdaq bagholders.

0 · Reply

BillionerOfKing Apr. 28 at 3:56 PM

$MTVA Current Stock Price: $1.60

0 · Reply

Kertzi Apr. 28 at 6:49 AM

$MTVA 128 pages filled with red flags, risks and going concern warnings. 🏴‍☠️🆘 https://www.sec.gov/Archives/edgar/data/1638287/000114036126016808/ny20067174x3_ars.pdf

0 · Reply

Joefreeagent Apr. 27 at 3:46 PM

$MTVA after losing 99.99% of your money, the executives need a pay increase. Lmao.

0 · Reply

MrTicker Apr. 22 at 1:26 PM

$MTVA volume picking up.. possible PR to release soon.. keep an eye on it

0 · Reply

luminouslumens Apr. 22 at 10:37 AM

$ELPW $FFAI $MTVA $BURU $ASBP Early premarket momentum scan, waiting for 7-8am volume / setups

0 · Reply

Joefreeagent Apr. 15 at 8:35 PM

$MTVA upto a 1 for 22 reverse split. To use anytime. Lmao.

0 · Reply

Market Cap	5.37M
Revenue (ttm)	0.00
Net Income (ttm)	-12.97M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	205,600
Avg Vol	152,424
Day's Range	N/A - N/A
Shares Out	5.16M
Stochastic %K	1%
Beta	0.59
Analysts	Strong Sell
Price Target	$19.33